Compass Pathways PLC Sponsored ADR $CMPS Stock: CenterBook Partners LP Boosts Stake

CenterBook Partners LP lifted its holdings in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 454.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 695,943 shares of the company’s stock after purchasing an additional 570,349 shares during the quarter. CenterBook Partners LP owned 0.50% of Compass Pathways worth $8,658,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Pekin Hardy Strauss Inc. purchased a new stake in Compass Pathways during the third quarter valued at $792,000. Commonwealth Equity Services LLC grew its stake in shares of Compass Pathways by 81.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 23,482 shares of the company’s stock worth $292,000 after buying an additional 10,510 shares in the last quarter. Integrity Alliance LLC. bought a new stake in shares of Compass Pathways in the 3rd quarter worth about $128,000. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Compass Pathways by 23.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 399,506 shares of the company’s stock worth $4,970,000 after buying an additional 76,297 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Compass Pathways during the 3rd quarter valued at about $85,000. Institutional investors own 46.19% of the company’s stock.

Compass Pathways Trading Up 10.2%

NASDAQ:CMPS traded up $0.80 during mid-day trading on Friday, hitting $8.61. 3,757,104 shares of the stock traded hands, compared to its average volume of 3,011,761. The company has a quick ratio of 1.30, a current ratio of 1.30 and a debt-to-equity ratio of 0.60. Compass Pathways PLC Sponsored ADR has a 52 week low of $4.88 and a 52 week high of $15.87. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of -2.47 and a beta of 2.43. The firm’s 50 day moving average is $12.32 and its two-hundred day moving average is $10.41.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.08. On average, equities research analysts predict that Compass Pathways PLC Sponsored ADR will post -0.83 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on CMPS. Morgan Stanley boosted their price objective on Compass Pathways from $17.00 to $18.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Oppenheimer reaffirmed an “outperform” rating and issued a $20.00 price objective on shares of Compass Pathways in a research note on Tuesday. BTIG Research reiterated a “buy” rating and issued a $25.00 target price on shares of Compass Pathways in a report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Pathways in a report on Thursday, October 15th. Finally, HC Wainwright decreased their price target on Compass Pathways from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $23.14.

Compass Pathways Company Profile

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.